Home » Newsletters » The Carlat Psychiatry Report

The Carlat Psychiatry Report

Bipolar II (March) | 2020

View Archived Issues

CME Post-Test - Bipolar II, TCPR, March 2020

March 9, 2020

The post-test for this issue is available for one year after the publication date to subscribers. By successfully completing the test you will be awarded a certificate for 1 CME credit. Read More

Oxcarbazepine: Close, but no Cigar

March 9, 2020

Oxcarbazepine is thought of as a kinder, gentler cousin of carbamazepine, but it brings new safety issues of its own and does not fully escape the drug interactions that hinder carbamazepine. We pull on the published and unpublished trials to figure out where this anticonvulsant stands in bipolar disorder. Read More

Psychopharmacology in Bipolar II

March 9, 2020

Tammas Kelly, MD

Bipolar II is a different illness from Bipolar I, but it’s in Bipolar I that most of the psychopharmacology research was undertaken. Dr. Kelly walks us through some of the nuances in applying that knowledge to Bipolar II, and shows us how to recognize the subtle traces of hypomania and mixed features that go along with Bipolar II depression. Read More

Lumateperone and lemborexant

March 9, 2020

The antipsychotic lumateperone (Caplyta) and the hypnotic lemborexant (Dayvigo) are the newest in their class. Both of them claim to improve on the safety of older medications, and we look at the data to see how those claims hold up. Read More

Optimal Antidepressant Doses in Major Depression

March 9, 2020

Kristen Gardner, PharmD.

More is not necessarily better in psychopharmacology. Some medications have plateau effect, while others follow a “U-shaped curve,” causing more problems as the dose goes too high. This metaanalysis looked at 77 dose-response trials with antidepressants to quantify their optimal therapeutic window. Read More